The European Medicines Agency's Committee for Medicinal Products for Human Use recommended that GlaxoSmithKline's Revolade be approved to treat a rare blood-clotting disorder called chronic immune thrombocytopenic purpura. The drug, which is expected to compete with Amgen's Nplate, works by inducing bone marrow to produce platelets in patients with ITP.

Full Story:

Related Summaries